MCID: LRG001
MIFTS: 45

Large Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Large Cell Carcinoma

MalaCards integrated aliases for Large Cell Carcinoma:

Name: Large Cell Carcinoma 11 14
Carcinoma, Large Cell 43 71
Carcinoma Large Cell 53

Classifications:



External Ids:

Disease Ontology 11 DOID:4552
MeSH 43 D018287
NCIt 49 C3780
SNOMED-CT 68 22687000
UMLS 71 C0206704

Summaries for Large Cell Carcinoma

Disease Ontology: 11 A carcinoma that is composed of large, monotonous rounded or overtly polygonal-shaped cells with abundant cytoplasm.

MalaCards based summary: Large Cell Carcinoma, also known as carcinoma, large cell, is related to thymus large cell carcinoma and large cell carcinoma with rhabdoid phenotype. An important gene associated with Large Cell Carcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Endometrial cancer and NF-kappaB Pathway. The drugs Everolimus and Erlotinib have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and lymph node, and related phenotypes are Decreased viability and homeostasis/metabolism

Related Diseases for Large Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 671)
# Related Disease Score Top Affiliating Genes
1 thymus large cell carcinoma 32.8 SYP KRT7 KRT5 CHGA
2 large cell carcinoma with rhabdoid phenotype 32.6 KRAS HRAS ENO2
3 lung large cell carcinoma 32.6 SYP NKX2-1 KRT7 KRT5 KRAS HRAS
4 pleomorphic carcinoma 31.9 NKX2-1 KRT7 KRT5 KRAS HRAS EGFR
5 large cell neuroendocrine carcinoma 31.9 SYP NKX2-1 KRT7 KRT5 KRAS HRAS
6 lung cancer 31.2 UCHL1 TP63 SYP SFTPB PTHLH NKX2-1
7 neuroendocrine carcinoma 30.9 TP63 SYP NKX2-1 MUC1 KRT7 KRT20
8 lung giant cell carcinoma 30.8 NKX2-1 KRT7 KRT5 KRAS EGFR
9 small cell cancer of the lung 30.8 SYP NKX2-1 KRT7 KRT20 ENO2 EGFR
10 carcinoid syndrome 30.7 SYP ENO2 CHGA
11 small cell carcinoma 30.7 SYP NKX2-1 KRT7 KRT5 KRT20 ENO2
12 carcinoid tumors, intestinal 30.7 SYP NKX2-1 ENO2 CHGA
13 neuroendocrine tumor 30.6 SYP PTHLH NKX2-1 KRT20 ENO2 CHGA
14 bronchus cancer 30.6 KRT7 ERBB2 ENO2 EGFR CEACAM5
15 lymphoepithelioma-like carcinoma 30.6 SYP KRT7 KRT5 KRT20 ENO2 EGFR
16 pulmonary large cell neuroendocrine carcinoma 30.6 SYP NKX2-1 ENO2 CHGA
17 basaloid squamous cell carcinoma 30.5 SYP NKX2-1 KRT7 KRT5 ENO2 CHGA
18 lung benign neoplasm 30.5 SYP NKX2-1 KRT7 KRT20 KRAS HRAS
19 intestinal obstruction 30.5 KRT7 KRT20 CEACAM5
20 adenocarcinoma 30.4 NKX2-1 MUC1 KRT7 KRT20 KRAS HRAS
21 rectum cancer 30.3 KRT20 KRAS HRAS EGFR CEACAM5 CEACAM3
22 lung squamous cell carcinoma 30.3 PTHLH KRAS HRAS EGFR CEACAM5
23 trachea carcinoma 30.3 NKX2-1 KRT7 KRT5 CEACAM5
24 solid adenocarcinoma with mucin production 30.2 NKX2-1 MUC1 KRT7 KRT5 CHGA
25 rectal benign neoplasm 30.2 KRT7 KRT20 KRAS HRAS EGFR CEACAM5
26 neurofibromatosis, type i 30.2 KRAS HRAS ENO2 EGFR
27 squamous cell carcinoma 30.2 TP63 PTHLH NKX2-1 MUC1 KRT7 KRAS
28 thymic carcinoma 30.1 TP63 SYP NKX2-1 MUC1 KRT7 KRT5
29 tubular adenocarcinoma 30.1 SYP MUC1 KRT7 KRT20 ERBB2 ENO2
30 benign mesothelioma 30.1 NKX2-1 KRT7 KRT5 KRT20 CEACAM5
31 vulva cancer 30.1 KRT7 HRAS ERBB2 EGFR CEACAM5
32 bladder urothelial carcinoma 30.1 KRT20 KRAS HRAS ERBB2
33 melanoma, uveal 30.1 HRAS ERBB2 EGFR CDK4
34 thymus cancer 30.1 NKX2-1 KRT7 KRT5 HRAS ERBB2 EGFR
35 skin benign neoplasm 30.0 TP63 KRT7 KRT5 KRT20 HRAS ENO2
36 suppression of tumorigenicity 12 30.0 SYP KRT5 HRAS ERBB2 ENO2 EGFR
37 squamous cell carcinoma, head and neck 29.9 TP63 HRAS ERBB2 EGFR CDK4
38 bronchiolo-alveolar adenocarcinoma 29.9 NKX2-1 KRT7 KRT20 KRAS HRAS EGFR
39 signet ring cell adenocarcinoma 29.8 MUC1 KRT7 KRT20 KRAS HRAS ERBB2
40 peripheral nervous system disease 29.8 UCHL1 SYP KRAS HRAS ERBB2 ENO2
41 lung cancer susceptibility 3 29.7 TP63 SFTPB NKX2-1 MUC1 KRT7 KRT20
42 adenosquamous carcinoma 29.7 TP63 PTHLH NKX2-1 MUC1 KRT7 KRT5
43 mesothelioma, malignant 29.6 TP63 SFTPB NKX2-1 MUC1 KRT7 KRT5
44 adenoid cystic carcinoma 29.6 TP63 MUC1 KRT7 KRT20 KRAS HRAS
45 gastric cancer 29.5 MUC1 KRT20 KRAS ERBB2 EGFR CHGA
46 ovarian cancer 29.5 MUC1 KRT7 KRT20 KRAS HRAS ERBB2
47 prostate cancer 29.3 TP63 PTHLH MUC1 KRT5 HRAS ERBB2
48 lung occult large cell carcinoma 11.3
49 lung mixed small cell and squamous cell carcinoma 11.2
50 large cell keratinizing variant squamous cell breast carcinoma 11.2

Graphical network of the top 20 diseases related to Large Cell Carcinoma:



Diseases related to Large Cell Carcinoma

Symptoms & Phenotypes for Large Cell Carcinoma

GenomeRNAi Phenotypes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.62 EGFR HRAS KRAS MUC1
2 Decreased viability GR00055-A-2 9.62 EGFR HRAS KRAS MUC1
3 Decreased viability GR00055-A-3 9.62 KRAS
4 Decreased viability GR00106-A-0 9.62 KRAS
5 Decreased viability GR00221-A-1 9.62 EGFR HRAS KRAS
6 Decreased viability GR00221-A-2 9.62 HRAS KRAS
7 Decreased viability GR00221-A-3 9.62 HRAS
8 Decreased viability GR00221-A-4 9.62 EGFR
9 Decreased viability GR00249-S 9.62 MUC1
10 Decreased viability GR00301-A 9.62 KRAS
11 Decreased viability GR00381-A-1 9.62 KRAS

MGI Mouse Phenotypes related to Large Cell Carcinoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 CDK4 CEACAM5 CGB5 CHGA EGFR ERBB2
2 growth/size/body region MP:0005378 10.28 CDK4 CEACAM5 CGB5 CHGA EGFR ENO2
3 neoplasm MP:0002006 10.25 CDK4 CEACAM5 EGFR ERBB2 HRAS KRAS
4 normal MP:0002873 10.24 CDK4 EGFR ERBB2 HRAS KRAS MUC1
5 endocrine/exocrine gland MP:0005379 10.18 CDK4 CEACAM5 CGB5 CHGA EGFR ERBB2
6 renal/urinary system MP:0005367 10.16 CDK4 CHGA EGFR HRAS KRAS KRT7
7 digestive/alimentary MP:0005381 10.15 CDK4 CEACAM5 EGFR ERBB2 HRAS KRAS
8 muscle MP:0005369 10.1 CDK4 CEACAM5 CHGA EGFR ERBB2 HRAS
9 no phenotypic analysis MP:0003012 10.07 CHGA EGFR HRAS KRAS MUC1 NKX2-1
10 limbs/digits/tail MP:0005371 10.02 EGFR ERBB2 KRAS KRT5 PTHLH TP63
11 cardiovascular system MP:0005385 10 CDK4 CEACAM5 CHGA EGFR ERBB2 HRAS
12 craniofacial MP:0005382 9.97 CDK4 EGFR ENO2 ERBB2 HRAS KRAS
13 behavior/neurological MP:0005386 9.97 CDK4 CEACAM5 ENO2 ERBB2 HRAS KRAS
14 respiratory system MP:0005388 9.65 EGFR ENO2 ERBB2 HRAS KRAS NKX2-1
15 integument MP:0010771 9.32 CDK4 EGFR ERBB2 HRAS KRAS KRT5

Drugs & Therapeutics for Large Cell Carcinoma

Drugs for Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
2
Erlotinib Approved, Investigational Phase 3 183319-69-9, 183321-74-6 176870
3 Protein Kinase Inhibitors Phase 3
4 Insulin, Globin Zinc Phase 3
5
Insulin Phase 3
6 Immunoglobulins Phase 3
7 Antibodies, Monoclonal Phase 3
8 Antibodies Phase 3
9 Mitogens Phase 3
10
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
11
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
12
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
13
Durvalumab Approved, Investigational Phase 2 1428935-60-7
14
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
15
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
16
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
17
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
18
Nivolumab Approved Phase 2 946414-94-4
19
Etoposide Approved Phase 2 33419-42-0 36462
20
Lenograstim Approved, Investigational Phase 2 135968-09-1
21
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
22
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
23
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
26 Pharmaceutical Solutions Phase 2
27 Vaccines Phase 1, Phase 2
28 Folic Acid Antagonists Phase 2
29 Folate Phase 2
30 Vitamin B9 Phase 2
31 Vitamin B Complex Phase 2
32 Albumin-Bound Paclitaxel Phase 1, Phase 2
33 Antimitotic Agents Phase 2
34 Tubulin Modulators Phase 2
35 Immunologic Factors Phase 2
36 Immune Checkpoint Inhibitors Phase 2
37 Antineoplastic Agents, Immunological Phase 2
38 Immunoglobulins, Intravenous Phase 2
39 Immunoglobulin G Phase 2
40
Etoposide phosphate Phase 2 16760419
41 Adjuvants, Immunologic Phase 2
42 Keratolytic Agents Phase 2
43 Angiogenesis Inhibitors Phase 2
44 Dermatologic Agents Phase 2
45 Endothelial Growth Factors Phase 2
46 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
47 Alkylating Agents Phase 2
48 Antineoplastic Agents, Alkylating Phase 2
49
Crizotinib Approved, Investigational Phase 1 877399-52-5 11626560
50
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 1 133585-56-5, 60-18-4, 556-02-5 1153 6057

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
2 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
3 Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib
4 Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel
5 A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment Unknown status NCT01497041 Phase 2 Docetaxel;Oxaliplatin
6 A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer Completed NCT00073398 Phase 1, Phase 2
7 A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer Recruiting NCT05198830 Phase 2 Cisplatin;Methoxyamine;Pemetrexed
8 Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Active, not recruiting NCT03110978 Phase 2
9 A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
10 A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) Active, not recruiting NCT01386385 Phase 1, Phase 2 Carboplatin;Paclitaxel;Veliparib
11 A Randomized Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients Terminated NCT00632203 Phase 2 Temozolomide
12 A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer Completed NCT02535325 Phase 1 Cisplatin;Methoxyamine;Methoxyamine Hydrochloride;Pemetrexed;Pemetrexed Disodium
13 An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Recruiting NCT04432207 Phase 1 IMU-201 (administered as PD1-Vaxx)
14 A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01441128 Phase 1 PF-02341066/PF-00299804
15 Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix Unknown status NCT01606293
16 A Multicenter, Single-blind, Pair-matched, Observational Clinical Trial of LUNSAFE Recruiting NCT05337163
17 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Recruiting NCT02194738 Carboplatin;Cisplatin;Crizotinib;Erlotinib;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed;Pemetrexed Disodium

Search NIH Clinical Center for Large Cell Carcinoma

Cochrane evidence based reviews: carcinoma, large cell

Genetic Tests for Large Cell Carcinoma

Anatomical Context for Large Cell Carcinoma

Organs/tissues related to Large Cell Carcinoma:

MalaCards : Lung, Cervix, Lymph Node, Endothelial, Brain, Thyroid, Small Intestine

Publications for Large Cell Carcinoma

Articles related to Large Cell Carcinoma:

(show top 50) (show all 1836)
# Title Authors PMID Year
1
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. 53 62
19339104 2009
2
[Poorly differentiated large cell endocrine carcinoma of the extrahepatic bile ducts]. 53 62
19233580 2009
3
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. 53 62
18452692 2008
4
Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin. 53 62
18078328 2008
5
[Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]. 53 62
18227018 2008
6
Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. 53 62
18404793 2008
7
Humoral hypercalcemia of malignancy in a patient with large cell carcinoma of the lung: report of case and review of literature. 53 62
17669716 2007
8
Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. 53 62
17192868 2007
9
[Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray]. 53 62
17062341 2006
10
[EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. 53 62
17069674 2006
11
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. 53 62
16552419 2006
12
Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. 53 62
15770690 2005
13
CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. 53 62
15722794 2005
14
Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. 53 62
15494931 2004
15
Metastatic bronchogenic carcinoma with human chorionic gonadotropin production manifesting as cerebellar hemorrhage--case report. 53 62
11561353 2001
16
The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer. 53 62
10622207 1999
17
Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression. 53 62
9458138 1997
18
Expression and localization of thrombomodulin in preneoplastic bronchial lesions and in lung cancer. 53 62
9099977 1997
19
Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). 53 62
9816303 1996
20
GRP receptors are present in non small cell lung cancer cells. 53 62
8806107 1996
21
The expression of trophoblastic cell markers by lung carcinomas. 53 62
7590693 1995
22
Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. 53 62
7669560 1995
23
Detection of thrombomodulin in human lung cancer cells. 53 62
8380956 1993
24
Pulmonary large cell carcinoma expressing neuroendocrine markers: the morphological, biological, and neuroendocrine features of their cell lines and surgical cases. 53 62
1331003 1992
25
Carcinoembryonic antigen content in fine needle aspirates of the lung. A diagnostic adjunct to cytology. 53 62
1580109 1992
26
Immunohistochemical detection of cluster 1 small cell lung cancer antigen and chromogranin A in lung carcinomas. 53 62
1315401 1992
27
Activated protooncogenes in human lung tumors from smokers. 53 62
1996309 1991
28
Comparison of cytologic markers for automated lung cancer screening. 53 62
1702634 1990
29
Large cell carcinoma of the lung secreting human chorionic gonadotropin which responded to combination chemotherapy: case report. 53 62
2174998 1990
30
Large cell carcinoma of the lung. Prognostic implications of histopathologic and immunohistochemical subtyping. 53 62
2154087 1990
31
The Clinical Characteristics and Treatments for Large Cell Carcinoma Patients Older than 65 Years Old: A Population-Based Study. 62
36358648 2022
32
CircRNA circ-PDCD11 is highly expressed in lung large-cell carcinoma and predicts poor survival. 62
36017647 2022
33
Selective Targeting and Eradication of Various Human Non-Small Cell Lung Cancer Cell Lines Using Self-Assembled Aptamer-Decorated Nanoparticles. 62
36015276 2022
34
The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. 62
35609368 2022
35
A multi-classification model for non-small cell lung cancer subtypes based on independent subtask learning. 62
35715882 2022
36
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114). 62
35322551 2022
37
Mandatory Nodal Evaluation During Resection of Clinical T1a Non-Small Cell Lung Cancers. 62
34358520 2022
38
Proteomic Analysis of Lung Cancer Types-A Pilot Study. 62
35681609 2022
39
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. 62
35428358 2022
40
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer. 62
35456982 2022
41
Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers. 62
35383703 2022
42
Essential Oils and Extracts of Juniperus macrocarpa Sm. and Juniperus oxycedrus L.: Comparative Phytochemical Composition and Anti-Proliferative and Antioxidant Activities. 62
35448753 2022
43
Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. 62
35329826 2022
44
Cytologic presentation of ovarian large cell carcinoma with rhabdoid features detected on peritoneal washing. Report of one case with cyto-histologic correlation and previously undescribed inactivating SMARCA-4 mutations. 62
34905290 2022
45
Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report. 62
35151345 2022
46
Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma. 62
35144629 2022
47
Correlation between the Treg/Thl7 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease. 62
35915772 2022
48
Exploration of the optimal number of regional lymph nodes removed for resected N0 NSCLC patients: A population-based study. 62
36249000 2022
49
THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY. 62
35442337 2022
50
Case Report: Combined Small Cell Lung Carcinoma With Pulmonary Adenocarcinoma. 62
35187062 2022

Variations for Large Cell Carcinoma

Expression for Large Cell Carcinoma

Search GEO for disease gene expression data for Large Cell Carcinoma.

Pathways for Large Cell Carcinoma

Pathways related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.6 KRAS HRAS ERBB2 EGFR CDK4
2
Show member pathways
12.31 KRAS HRAS ERBB2 EGFR
3
Show member pathways
12.26 KRAS HRAS ERBB2 EGFR CDK4
4
Show member pathways
12.25 MUC1 KRAS HRAS ERBB2 EGFR
5
Show member pathways
12.14 KRAS HRAS ERBB2 EGFR
6
Show member pathways
12.11 KRAS HRAS CEACAM5 CEACAM3
7
Show member pathways
12.08 KRAS HRAS ERBB2 EGFR CDK4
8
Show member pathways
11.96 KRAS HRAS ERBB2 EGFR
9
Show member pathways
11.92 KRAS HRAS ERBB2 EGFR
10
Show member pathways
11.84 KRAS HRAS ERBB2 EGFR CDK4
11
Show member pathways
11.83 EGFR ERBB2 HRAS KRAS
12 11.81 CHGA EGFR HRAS KRAS
13
Show member pathways
11.72 ERBB2 EGFR CGB5
14 11.38 EGFR ERBB2 HRAS KRAS
15 11.37 EGFR HRAS KRAS
16 11.29 HRAS ERBB2 EGFR
17 11.16 KRAS HRAS EGFR
18
Show member pathways
11.01 KRAS HRAS EGFR
19 10.96 KRAS HRAS ERBB2 EGFR CDK4
20 10.96 TP63 KRAS HRAS ERBB2 EGFR CDK4
21 10.9 KRAS HRAS ERBB2 EGFR
22
Show member pathways
10.68 KRAS HRAS

GO Terms for Large Cell Carcinoma

Biological processes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 9.77 TP63 PTHLH KRAS HRAS ERBB2 EGFR
2 epidermis development GO:0008544 9.63 TP63 PTHLH KRT5 EGFR
3 regulation of long-term neuronal synaptic plasticity GO:0048169 9.1 SYP KRAS HRAS

Sources for Large Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....